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ABSTRACT
Acute pain, prevalent as part of postoperative
and traumatic pain, is often sub-optimally or
inadequately treated. Fixed-dose combination
analgesic products that combine a reduced
amount of opioid with a nonopioid analgesic
such as acetaminophen (paracetamol) in a
single tablet offer potential pharmacodynamic
and/or pharmacokinetic benefits, and may also
result in an opioid-sparing effect. A new
analgesic product (XARTEMISTM XR,
Mallinckrodt Brand Pharmaceuticals, Dublin,
Ireland) combines oxycodone (7.5 mg) with
acetaminophen (325 mg) in an immediate-
release/extended-release (ER) formulation that
is indicated for the treatment of acute pain. The
ER formulation of this product provides stable
serum drug concentrations that in this case lasts
12 h. Oxycodone/acetaminophen is a drug
combination that offers safe and effective pain
relief in a variety of acute pain syndromes such
as postoperative pain. The combination
formulation allows a smaller amount of
oxycodone per tablet and the biphasic-layered
matrix of the pill for ER may present obstacles
to potential abusers. No opioid is totally abuse
resistant, but the lower opioid content and
tamper-resistant formulation of this product
might discourage abuse. Clinicians must still
be mindful of the acetaminophen part of this
product in the patient’s overall daily intake (in
light of acetaminophen hepatotoxicity). The
new product appears to provide an important
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new choice in the armamentarium against
acute pain.
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INTRODUCTION
Acute pain is prevalent and often under-treated
[1, 2] that results in increased suffering and
distress, delayed rehabilitation and healing, and
may transition to chronic pain (a process
known as chronification) [3, 4]. Acute pain
may occur following surgical procedures,
trauma, or illness. Even when acute pain is
predictable and occurs in a controlled setting
(such as inpatient surgery), pain is often less-
than-optimally treated. In a survey of 250 adults
who had surgery as an in- or outpatient in the
last 5 years, 82% reported at least some degree
of pain in the period of up to 2 weeks after
surgery; 21% and 18% of these respondents
categorized the postsurgical pain as severe or
extreme, respectively [5]. In a French survey
among 750 adult patients 24 h following
surgery, 87% reported postsurgical pain with
half (50.9%) categorizing that pain as severe [6].
A German multicenter study (n = 2252 patients
who underwent surgery or other procedure)
found that 88% of patients were in pain 24 h
after their treatment, with non-surgical patients
experiencing slightly higher rates of under-
treated pain [7]. In a survey of 50,869 patients
with acute pain of various etiologies (surgery,
trauma, postherpetic neuralgia, low back pain,
and other conditions), 44% reported inadequate
analgesia [8].
The pharmacological armamentarium for
managing acute pain includes nonopioid
agents, notably acetaminophen (paracetamol),
nonsteroidal anti-inflammatory drugs (NSAIDs),
and anticonvulsants [9], although their efficacy
in acute pain is debatable; and opioids for
moderate to severe or very severe pain. Risks
and benefits attach to each of these agents.
Acetaminophen has been associated with liver
damage [10]. NSAIDs have been associated with
gastrointestinal side effects and cardiovascular
adverse events [11, 12]. Opioids are associated
with potentially treatment-limiting side effects.
In a survey of 50,869 patients with acute pain,
37% of those treated with a strong opioid
discontinued their medication before pain
resolved because of intolerable side effects [8].
Thus, the undertreatment of acute pain may
sometimes be due to the fact an analgesic
product was not tolerated, rather than the fact
that no analgesics were prescribed.
LONG-ACTING FORMULATIONS
XARTEMISTM XR (previously known as MNK-
795, Mallinckrodt Brand Pharmaceuticals,
Dublin, Ireland), is the first immediate-release
(IR)/extended-release (ER) abuse-deterrent
formulation comprised of a fixed-dose
combination of oxycodone (7.5 mg) plus
acetaminophen (325 mg) that is available on
the market. While there are no consensus
definitions for terms such as ‘‘long acting’’,
‘‘short acting’’, ‘‘immediate release’’,
‘‘controlled release’’, or ‘‘extended release’’ [13],
it is generally accepted that short-acting opioids
(e.g., morphine, oxycodone) have a duration of
action of about 2–4 h, while a long-acting
opioid maintains therapeutic serum
concentration for 12–24 h (e.g., methadone,
tramadol) [14, 15]. By this convention,
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XARTEMISTM XR would be classified as long-
acting, even though it has a short-acting
component. Clinical intuition would hold that
long-acting analgesics offer certain potential
advantages: reduced pill burden, greater
convenience [16], more sustained serum drug
concentration [17], and reduction of ‘‘end-of-
dose’’ phenomena or ‘‘analgesic gaps’’ between
doses [18]. XARTEMISTM XR was designed to
incorporate rapidity of analgesic onset
combined with long duration of action. The
intended result is better overall pain control.
Analgesic effect is related to serum drug
concentration; the minimum effective
concentration (MEC) defines the level of
serum drug level required to provide analgesia
[19]. Thus, providing a consistent serum drug
concentration above the MEC for a prolonged
period of time may confer greater analgesia
than a short-acting agent. A caveat is that head-
to-head studies comparing long-acting to short-
acting analgesic agents are few and the evidence
is still equivocal. For example, in a study of
cancer patients treated with long-acting and
short-acting opioids, patients in the long-acting
opioid group had significantly lower pain
intensity scores (P = 0.008) and better quality
of life than patients in the short-acting opioid
group [16], but other studies found long-acting
and short-acting opioids conferred similar
analgesic benefits [20, 21]. A double-blind
clinical trial that compared ER oxycodone to
IR fixed-dose oxycodone/acetaminophen
analgesics in patients with osteoarthritis with
chronic pain found similar pain control
between agents, but the patients taking the ER
product reported significantly better sleep
quality [22]. In a randomized, double-blind
study of patients with cancer pain, patients
taking sustained-release oral morphine reported
significantly less tiredness than those taking IR
oral morphine [23].
Many opioid-related adverse events, such as
respiratory depression, are dose related. The
more constant serum concentration levels
resulting from long-acting opioids avoid the
peak-to-trough transitions of short-acting
opioids, and have been thought to offer
greater tolerability [13]. Evidence supporting
reduced side effects in long-acting versus short-
acting opioid agents, though, has been mixed
[14, 21, 22, 24]. Comparative studies of opioid
analgesic agents are complicated by the fact
that pain is subjective, variable, and that
patients do not respond similarly to opioids;
for instance, there is no clear evidence that any
one opioid agent is clinically superior to the
others, although individual patients may
respond better to one than another.
There are reasons why prescribers might
select long-acting analgesic agents over short-
acting agents for their patients: long-acting
formulations may provide analgesic benefit for
12–24 h [15]; long-acting agents may provide
sufficiently long pain control to permit
uninterrupted sleep; and long-acting agents
reduce frequent dosing, which patients may
prefer and which might improve compliance
which, in turn, could improve analgesic relief.
There appears to be widespread clinical
acceptance of long-acting opioids, as
evidenced by the fact that 23 million ER
prescriptions were dispensed in the United
States (US) in 2009 [25].
ER formulations are available for single-
entity opioids, such as hydrocodone,
hydromorphone, morphine, oxycodone, and
tapentadol. Transdermal buprenorphine and
transdermal fentanyl may also be considered
long-acting single-entity opioid analgesics.
Single-entity ER hydrocodone was cleared for
market by the US Food and Drug
Administration (FDA) under considerable
controversy, in that its Advisory Panel
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recommended against approval [26–28].
XARTEMISTM XR is the only IR/ER formulation
of a fixed-dose oxycodone/acetaminophen





A fixed-dose combination analgesic is a product
that combines two or more agents into a single
tablet or capsule to offer additive or synergistic
analgesic benefits, or reduce overall adverse
effects (AEs) [29]. A further benefit of opioid/
nonopioid fixed-dose combination products is
that they may provide analgesia using a lower
dose of opioid, resulting in a so-called ‘‘opioid-
sparing effect’’ [30]. The synergistic
combination of oxycodone plus
acetaminophen shown in animal models has
been reflected in safe and effective pain relief in
many types of clinical pain syndromes [30],
including low back pain [31], rheumatic
conditions [32–34], postsurgical pain [35–37],
pain following dental procedures [38], acute
pain [39], and cancer pain [40].
XARTEMISTM XR was evaluated in a
randomized, double-blind, placebo-controlled
study of 266 bunionectomy patients [41].
Patients were administered four doses (2
tablets every 12 h) of oxycodone/
acetaminophen ER product or placebo. The
mean summed pain intensity difference at
48 h was 114.9 (±7.6) for the active group and
66.9 (±7.6) for the placebo group (P\0.0001),
with the treatment group achieving meaningful
pain relief significantly sooner than the control
patients. After the first 30 min, the treatment-
group patients had C30% pain intensity relief at
all of the time points versus placebo. Placebo-
group patients took more supplemental/rescue
medication (i.e., ibuprofen, 400 mg every 6 h)
over 48 h than did the active-group patients
(4.64 vs. 2.91 doses, respectively, P\0.0001).
More patients in the treatment than placebo
group reported AEs (53.6% vs. 21.5%,
respectively), but the rate of constipation was
low (4.2% vs. 3.1%, respectively) which may
have been attributable to the short duration of
the study. Other AEs included nausea (30.7% vs.
5.5%), dizziness (13.3% vs. 1.2%), headache
(9.6% vs. 4.9%), skin disorders (9.0% vs. 4.3%),
vomiting (9.0% vs. 0%), and somnolence (3.6%
vs. 0.6%).
In an open-label extension study of the
above trial lasting at least 14 days, tolerability
of XARTEMISTM XR was consistent with that of
an opioid product and AEs occurred in 43.8% of
patients [42]. The most common AEs reported
in this extension study were nausea (17.8%),
vomiting (7.5%), and constipation (6.2%).
In an analysis of 20 studies of XARTEMISTM
XR (n = 2641 patients total), the number needed
to treat for at least 50% pain relief was 4.6 (95%
confidence interval, range 2.9–11) for single-
entity oxycodone and 2.7 (95% confidence
interval, range 2.4–3.1) for oxycodone/
acetaminophen 10/650 mg (an IR product) [35].
CONSIDERATIONS FOR THE USE
OF ACETAMINOPHEN IN FIXED-
DOSE PRODUCTS
Acetaminophen is the most frequently
consumed analgesic in the US [43, 44]. The
FDA has launched various public health
initiatives regarding this familiar drug’s
potential hepatotoxicity, and it recommends
that adult doses be limited to no more than
4000 mg per day, which is higher than the
3000 mg maximum daily dose on current
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products marketed by McNeill Consumer
Healthcare, a Johnson & Johnson company
[45, 46]. Since this total daily dose is
cumulative from all sources, the FDA further
limits the dose of acetaminophen allowed in
prescription combination products [47]. Despite
these efforts, however, consumers may be
unaware of potential acetaminophen toxicity
or be unaware of all of the sources of
acetaminophen in their medicine cabinets
[48–50].
XARTEMISTM XR contains 325 mg of
acetaminophen per tablet, which falls within
the new FDA requirements (2 tablets = 650 mg
acetaminophen, 4 tablets = 1300 mg
acetaminophen/day). However, patient
education is still necessary when prescribing a
product that contains acetaminophen.
Clinicians who prescribe a product containing
acetaminophen should be diligent about
informing patients about toxicity and dose
limits.
The risk of hepatotoxicity was evaluated in a
large retrospective cohort study of 1,228,356
adults taking either oxycodone/acetaminophen
or hydrocodone/acetaminophen products
compared to controls taking opioids only [51].
After adjusting for confounders, the opioid-only
group did not exhibit a lower rate of
hepatotoxicity-related hospitalizations at
12 months than did the groups taking
oxycodone or hydrocodone combination
products with acetaminophen. To date, there
are no strong population-based data indicating
that fixed-dose combination products
containing acetaminophen elevate the
patient’s risk of hepatotoxicity-related
hospitalization. Nevertheless, diligence must
be exercised.
DRUG DELIVERY TECHNOLOGY
The XARTEMISTM XR product was designed as a
dual-layer product to allow for biphasic drug
delivery as well as provide resistance to some
tampering methods. A partial amount of the
agents is released immediately for rapid onset of
pain relief, followed by a gradual, sustained
release of the remainder over 12 h [52]. Each
tablet contains a release-controlling polymer
that swells in the stomach, extending drug
release. When taken as a single dose (two
tablets, oxycodone/acetaminophen), the IR
layer delivers approximately 3.75/325 mg of
oxycodone/acetaminophen followed by the
release from the ER layer of approximately
11.25/325 mg of oxycodone/acetaminophen.
The use of the polymer technology was
evaluated in a phase I study to determine if
food intake might affect the pharmacokinetic
properties. A study of 48 health volunteers (men
and women, ages 18–55 years, body mass
indices ranging from 19 to 30) in an open-
label, single-center, three-period, six-sequence,
crossover study over 13 weeks found small
differences in maximum serum concentration
(Cmax) for oxycodone and acetaminophen in
fed versus fasted subjects, but these differences
were deemed not large enough to have clinical
relevance [53]. The area-under-the-time curve
(AUC) 0 to infinity and AUCo–t were nearly
identical in fed and fasted subjects. The
bioavailability of both oxycodone and
acetaminophen was within the acceptable
limit of 80–125% for the 90% confidence
interval for the geometric least squares mean
ratio for AUC and Cmax for high-fat state versus
fasted state. Thus, it does not appear that the
level of food intake will affect the product’s
Adv Ther (2015) 32:485–495 489
pharmacokinetics; the package insert indicates




FOR CHRONIC PAIN SYNDROMES
XARTEMISTM XR is indicated for acute pain
[54]. Although many guidelines recommend
opioid analgesics for chronic pain conditions
[55–57], including for geriatric patients [58, 59],
the use of opioids for chronic nonmalignant
pain remains controversial [60–62]. In a
retrospective review, fixed-dose IR oxycodone–
acetaminophen combination products were the
most frequently prescribed drugs for patients
with chronic noncancer pain [63], and they
have demonstrated safety and efficacy in the
treatment of chronic pain syndromes [30, 32,
34]. It must be noted that this is off-label use
and the authors are not advocating such use.
ABUSE POTENTIAL OF EXTENDED-
RELEASE OXYCODONE/
ACETAMINOPHEN
In 2009, the FDA stated that there was a need
for a class-wide Risk Evaluation and Mitigation
Strategy (REMS) for ER opioids, and such was
proposed the following year and approved in
2012 [64]. A key consideration for REMS is that
ER single-entity opioid formulations contain
more opioid per dosage unit than do
comparable IR formulations, and larger doses
are thought to be associated with an elevated
risk of abuse [65]. Moreover, long-acting single-
entity opioids have been associated with higher
rates of overdose [66]. There is no comparable
class-wide REMS for IR opioids, which may have
led to the otherwise unsupported notion that IR
opioids products are somehow ‘‘safer’’ than ER
opioids. Fixed-dose combination products can
contain a relatively small amount of opioid,
which in theory is less attractive to potential
abusers. Currently XARTEMISTM XR does not
have a REMS requirement.
The abuse potential for long-acting
compared to short-acting opioid formulations
remains to be elucidated. For instance, opioid
abusers tend to prefer the effects of IR products
compared to ER products [67], but they may opt
to abuse ER products if they can extract the
drug, because ER single-entity products contain
larger quantities of opioid. Since opioids are
often abused by people who are not patients,
but by those who obtain prescription pain
relievers from family or friends [68], opioid
selection is often based on what is available.
The biphasic-layered structure of
XARTEMISTM XR may resist or deter potential
abuse. Abuse-deterrent formulations represent
an important effort to reduce opioid abuse
[69, 70], but long-term longitudinal studies are
needed to ascertain their true impact on opioid
abuse. The new product contains a smaller
amount of oxycodone per tablet (7.5 mg) and
that appears to be relatively difficult to extract
due to the incorporation of the PolyOxTM (The
Dow Chemical Company Midland, MI, USA)
polymer [71]. The acetaminophen content of
the tablets may deter some abusers, who may be
concerned about the potential hepatotoxic risk
of high doses.
Although the combination of
acetaminophen with an opioid may make the
drug less attractive to abusers, combination
products may still be abused and, in such
cases, the abuser may suffer from
acetaminophen poisoning. For example,
patients who crush combination products to
‘‘snort’’ or to inhale them may absorb
potentially toxic concentrations of
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acetaminophen [72, 73]. There is relatively little
research into the pharmacokinetics of nasal
acetaminophen.
CLINICAL PERSPECTIVE
XARTEMISTM XR is the only available long-
acting formulation of the frequently prescribed
combination of oxycodone and
acetaminophen. While IR oxycodone/
acetaminophen and other opioid/nonopioid
fixed-dose products are available, they are all
short-acting formulations. But pain may last for
several days or weeks before it diminishes or
resolves, and an ER formulation allows for more
convenient dosing, decreases the pill burden,
and offers more steady serum concentrations
than do IR products. It is easy to speculate on
potential advantages of this sort of ER product:
it may allow for patients to get a full night’s
sleep, it may improve their ability to resume
everyday activities with prolonged pain relief,
and it may be better accepted by patients who
often dislike having to take pills every 4–6 h.
The opioid-sparing benefits of this combination
product provide analgesic relief with a relatively
small quantity of opioid. Thus, there are some
immediate reasons to welcome this product.
However, ER opioid formulations do have
some drawbacks. For example, ER formulations
are generally not appropriate to treat
breakthrough pain. If one was to treat
breakthrough pain with ER formulations,
increasing the dose, as is generally the
practice, exposes the patient to more than
necessary medication, which can lead to more
sedation and side effects. Appropriate treatment
depends on the type and duration of
breakthrough pain and generally includes
short-acting opioids such as oxycodone and
morphine with fentanyl formulations used for
very short duration, rapid-onset breakthrough
pain. Another drawback is the potential for
abuse. While public health initiatives have done
much to decrease opioid abuse [74, 75], it
remains a serious problem. For some outside
the clinical community, eliminating or vastly
restricting opioid analgesics seems like a viable
solution to prescription analgesic abuse, but
this would leave much moderate-to-severe pain
untreated. Responsible prescribing involves
balanced and measured steps. As a Schedule II
controlled substance, this new oxycodone/
acetaminophen product will be closely
regulated and it lacks some of the features that
make opioid analgesics particularly ‘‘likeable’’ in
the eyes of potential abusers. No opioid
analgesic is totally abuse-proof, but this
formulation might be less likely to become a
prime target for potential abusers. However,
much work is still necessary on the part of
clinicians to educate patients and their
caregivers and families about the appropriate
use of all opioid formulations and potential for
misuse of opioid therapy.
Long-acting oxycodone/acetaminophen
seems to be an important new option. It
might offer equianalgesic benefits to patients
with acute pain without exposing them to the
greater quantity of opioids contained in single-
entity opioid therapy. It will offer more stable
serum concentrations, and its convenient
dosing might improve patient adherence.
CONCLUSION
To the armamentarium for pain control has been
added a long-acting fixed-dose combination
product of oxycodone/acetaminophen (7.5/
325 mg), XARTEMISTM XR, which is indicated
for the management of moderate to severe acute
pain. The synergistic combination of oxycodone
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with acetaminophen demonstrated in animal
models is well established as being safe and
effective in numerous painful conditions,
including postsurgical and posttraumatic pain.
The new long-acting formulation should offer
more stable serum drug concentrations than
short-acting formulations and provide 12 h or
more of pain relief. Its abuse potentialmaybe less
because of the lower amount of oxycodone per
tablet and the difficulty associated with
extracting it. As usual, good clinical practice
dictates individualized patient care and
counseling patients about potential AEs,
acetaminophen toxicity and dose limitations,
and potential for opioid misuse and abuse.
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